

=> s (cyclosporin A or CsA)  
L1 35100 (CYCLOSPRIN A OR CSA)

=> s (dimethyl sulfoxide or DMSO)  
L2 164887 (DIMETHYL SULFOXIDE OR DMSO)

=> s l1 and l2  
L3 590 L1 AND L2

=> s l3 and (pharmaceut? or therapeut?(3l)composition or formulation)  
L4 422 L3 AND (PHARMACEUT? OR THERAPEUT?(3L) COMPOSITION OR FORMULATIO  
N)

=> s l4 and (administer? or inject?)  
L5 393 L4 AND (ADMINISTER? OR INJECT?)

=> s l5 and (intraventricular or intrathecal)  
L6 62 L5 AND (INTRAVENTRICULAR OR INTRTHECAL)

=> s l5 and (intra-ocular or intravestibular)  
L7 3 L5 AND (INTRA-OCULAR OR INTRAVESTIBULAR)

=> dis l7 1-3 bib ab

L7 ANSWER 1 OF 3 USPATFULL  
AN 2001:102825 USPATFULL  
TI Alpha 1a adrenergic receptor antagonists  
IN Patane, Michael A., Harleysville, PA, United States  
Selnick, Harold G., Ambler, PA, United States  
Bock, Mark G., Hatfield, PA, United States  
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)  
PI US 6255315 B1 20010703  
AI US 1999-458169 19991209 (9)  
RLI Division of Ser. No. US 1998-99031, filed on 17 Jun 1998, now patented,  
Pat. No. US 6037354  
PRAI US 1997-49921P 19970618 (60)  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Rao, Deepak R.  
LREP Walton, Kenneth R., Winokur, Melvin  
CLMN Number of Claims: 30  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 4169  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as alpha 1a adrenergic receptor antagonists. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.

L7 ANSWER 2 OF 3 USPATFULL  
AN 2001:67681 USPATFULL  
TI Oxazolidinones useful as alpha 1a adrenoceptor antagonists  
IN Nerenberg, Jennie B., Maple Glen, PA, United States  
Bock, Mark G., Hatfield, PA, United States

Patane, Michael A., Harleysville, PA, United States  
Selnick, Harold G., Ambler, PA, United States  
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)  
PI US 6228870 B1 20010508  
AI US 1999-437841 19991110 (9)  
PRAI US 1998-107838P 19981110 (60)  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Dentz, Bernard  
LREP Fitch, Catherine D., Walton, Kenneth R., Winokur, Melvin  
CLMN Number of Claims: 29  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 2099

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel hydroxymethyl- and alkoxymethyl-oxazolidinone compounds and **pharmaceutically** acceptable salts thereof are disclosed. The synthesis of these compounds and their use as alpha 1a adrenergic receptor antagonists is also described. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia can be achieved.

L7 ANSWER 3 OF 3 USPATFULL

AN 2000:31428 USPATFULL

TI Alpha 1a adrenergic receptor antagonists

IN Patane, Michael A., Harleysville, PA, United States  
Selnick, Harold G., Ambler, PA, United States  
Bock, Mark G., Hatfield, PA, United States

PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

PI US 6037354 20000314

AI US 1998-99031 19980617 (9)

PRAI US 1997-49921P 19970618 (60)

DT Utility

FS Granted

EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Rao, Deepak R.

LREP Winokur, Melvin, Walton, Kenneth R.

CLMN Number of Claims: 29

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 4142

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as alpha 1a adrenergic receptor antagonists. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.

=> s 15 and (intravenous or intrarterial or intraparenchymal)

L8 296 L5 AND (INTRAVENOUS OR INTRARTERIAL OR INTRAPARENCHYMAL)

=> s l5 and (orally or rectally or nasally or dermally)

L9 267 L5 AND (ORALLY OR RECTALLY OR NASALLY OR DERMALLY)

=> s l6 and l7

L10 0 L6 AND L7

=> s l8 and l9

L11 210 L8 AND L9

=> s l6 and l11

L12 60 L6 AND L11

=> s l7 and l12

L13 0 L7 AND L12

=> s l12 and (cerebrospinal or vascular)

L14 44 L12 AND (CEREBROSPINAL OR VASCULAR)

=> s l14 and (brain or spinal cord)

L15 43 L14 AND (BRAIN OR SPINAL CORD)

=> s l15 and (adminster? or inject?(3l) patient)

L16 43 L15 AND (ADMINSTER? OR INJECT?(3L) PATIENT)

=> s l16 and (pharmceutical formulation or compositio)

L17 0 L16 AND (PHARMCEUTICAL FORMULATION OR COMPOSITIO)

=> s l16 and (pharmaceutical formulation or composition)

L18 32 L16 AND (PHARMACEUTICAL FORMULATION OR COMPOSITION)

=> s l18 and (treatment disease or condition)

L19 30 L18 AND (TREATMENT DISEASE OR CONDITION)

=> s l19 and (cerebrospinal fluid space)

L20 0 L19 AND (CEREBROSPINAL FLUID SPACE)

=> s l19 (cerebrospinal space)

MISSING OPERATOR 'L152 (CEREBROSPI'

The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> s l19 and (cerebrospinal space)

L21 0 L19 AND (CEREBROSPINAL SPACE)

=> s l19 and (cerebrospial)

L22 0 L19 AND (CEREBROSPIAL)

=> s l19 and (intra-ocular or intravestibular)

COMMAND INTERRUPTED

L23 0 L19 AND (INTRA-OCULAR OR INTRAVESTIBULAR)

If this message appears repeatedly, please notify the Help Desk.

Enter "HELP STN" for information on contacting the nearest STN Help Desk by telephone or via SEND in the STNMAIL file.

=> dis l9 1-10 bib ab

L9 ANSWER 1 OF 267 USPATFULL

AN 2003:65395 USPATFULL

TI Novel non-imidazole compounds

IN Aslanian, Robert G., Rockaway, NJ, UNITED STATES

Shih, Neng-Yang, North Caldwell, NJ, UNITED STATES

Ting, Pauline C., New Providence, NJ, UNITED STATES

Berlin, Michael Y., Flemington, NJ, UNITED STATES

Rosenblum, Stuart B., West Orange, NJ, UNITED STATES  
McCormick, Kevin D., Edison, NJ, UNITED STATES  
Tom, Wing C., Cedar Grove, NJ, UNITED STATES  
Boyce, Christopher W., Flemington, NJ, UNITED STATES  
Mangiaracina, Pietro, Monsey, NY, UNITED STATES  
Mutahi, Mwangi W., Fords, NJ, UNITED STATES  
Piwinski, John J., Clinton Township, NJ, UNITED STATES

PI US 2003045519 A1 20030306  
AI US 2001-978267 A1 20011015 (9)  
PRAI US 2000-240901P 20001017 (60)  
DT Utility  
FS APPLICATION  
LREP SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000  
GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530  
CLMN Number of Claims: 55  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 2838  
AB Disclosed are novel compounds of the formula ##STR1##

Also disclosed are **pharmaceutical** compositions comprising the compounds of Formula I.

Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I.

Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I in combination with a H.sub.1 receptor antagonist.

L9 ANSWER 2 OF 267 USPATFULL  
AN 2003:57074 USPATFULL  
TI Carbon monoxide improves outcomes in tissue and organ transplants and suppresses apoptosis  
IN Bach, Fritz H., Manchester-by-the-Sea, MA, UNITED STATES  
Otterbein, Leo E., New Kensington, PA, UNITED STATES  
Soares, Miguel P., Boston, MA, UNITED STATES  
Tobiasch, Edda M., Bonn, GERMANY, FEDERAL REPUBLIC OF  
Gose, Jeanne, Manchester-by-the-Sea, MA, UNITED STATES  
PI US 2003039638 A1 20030227  
AI US 2002-177930 A1 20020621 (10)  
PRAI US 2001-300289P 20010621 (60)  
US 2001-334340P 20011129 (60)  
US 2001-337974P 20011207 (60)  
DT Utility  
FS APPLICATION  
LREP FISH & RICHARDSON PC, 225 FRANKLIN ST, BOSTON, MA, 02110  
CLMN Number of Claims: 149  
ECL Exemplary Claim: 1  
DRWN 31 Drawing Page(s)  
LN.CNT 3473  
AB The present invention features methods for transplanting organs, tissues and individual cells. Also featured are methods for maintaining cells in vitro and for enhancing survival and/or function of cells following transplantation. The methods include the administration of carbon monoxide in an amount sufficient to enhance cell survival and/or function.

L9 ANSWER 3 OF 267 USPATFULL  
AN 2003:53823 USPATFULL  
TI Antirheumatic  
IN Matsumoto, Saichi, Ikeda, JAPAN  
Jyoyama, Hirokuni, Nara, JAPAN

Kakudo, Shinji, Kawanishi, JAPAN  
Hanasaki, Kohji, Kyoto, JAPAN  
Koizumi, Kenzo, Sakai, JAPAN  
Sakata, Tsuneaki, Toyonaka, JAPAN  
Suzuki, Ryuji, Ikoma, JAPAN  
PA Shionogi & Co., Ltd., Osaka, JAPAN (non-U.S. corporation)  
PI US 6525081 B1 20030225  
WO 9921844 19990506  
AI US 2000-530082 20000424 (9)  
WO 1998-JP4774 19981022  
PRAI JP 1997-292517 19971024  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Gerstl, Robert  
LREP Wenderoth, Lind & Ponack, L.L.P.  
CLMN Number of Claims: 12  
ECL Exemplary Claim: 1  
DRWN 7 Drawing Figure(s); 7 Drawing Page(s)  
LN.CNT 2111  
AB A novel antirheumatic agent comprising as an active ingredient a compound of formula I: ##STR1##

or a **pharmaceutically** acceptable salt or hydrate thereof.

L9 ANSWER 4 OF 267 USPATFULL  
AN 2003:45323 USPATFULL  
TI Heterocyclic esters and amides  
IN Li, Jia-He, Cockeysville, MD, UNITED STATES  
Hamilton, Gregory S., Catonsville, MD, UNITED STATES  
PI US 2003032635 A1 20030213  
AI US 2002-177666 A1 20020624 (10)  
RLI Continuation of Ser. No. US 2000-733043, filed on 11 Dec 2000, PENDING  
Division of Ser. No. US 1998-27622, filed on 23 Feb 1998, GRANTED, Pat.  
No. US 6200972 Continuation of Ser. No. US 1996-719947, filed on 25 Sep  
1996, GRANTED, Pat. No. US 5801187  
DT Utility  
FS APPLICATION  
LREP GUILFORD PHARMACEUTICALS C/O, FOLEY & LARDNER, 3000 K STREET, NW,  
WASHINGTON, DC, 20007-5143  
CLMN Number of Claims: 35  
ECL Exemplary Claim: 1  
DRWN 2 Drawing Page(s)  
LN.CNT 886  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB This invention relates to neurotrophic low molecular weight, small  
molecule heterocyclic ester and amides having an affinity for FKBP-type  
immunophilins, and their use as inhibitors of the enzyme activity  
associated with immunophilin proteins, particularly peptidyl-prolyl  
isomerase, or rotamase, enzyme activity.

L9 ANSWER 5 OF 267 USPATFULL  
AN 2003:45314 USPATFULL  
TI Substituted naphthyl indole derivatives as inhibitors of plasminogen  
activator inhibitor type-1 (PAI-1)  
IN Mayer, Scott Christian, Bridgewater, NJ, UNITED STATES  
Gundersen, Eric Gould, Hightstown, NJ, UNITED STATES  
Elokda, Hassan Mahmoud, Yardley, PA, UNITED STATES  
Crandall, David LeRoy, Doylestown, PA, UNITED STATES  
PA Wyeth, Madison, NJ, 07940 (U.S. individual)  
PI US 2003032626 A1 20030213  
AI US 2002-171041 A1 20020613 (10)  
PRAI US 2001-299651P 20010620 (60)  
DT Utility  
FS APPLICATION  
LREP Wyeth, 5 Giralda Farms, Madison, NJ, 07940

CLMN Number of Claims: 27  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1368  
AB This invention provides PAI-1 inhibiting compounds of Formula I:  
##STR1##

wherein: R.sub.1, R.sub.2, R.sub.3, and R.sub.4 are each H, alkyl, alkanoyl, halo, OH, aryl optionally substituted with R.sub.8, perfluoroalkyl, alkoxy, amino, alkylamino, dialkylamino, perfluoroalkoxy; R.sub.5 is H, alkyl, perfluoroalkyl, aryl optionally substituted with R.sub.8, alkanoyl, aroyl optionally substituted with R.sub.8; R.sub.6 is H, alkyl, alkylaryl, benzyl optionally substituted with R.sub.8, alkanoyl, aroyl optionally substituted with R.sub.8; R.sub.7 is H, alkyl, alkylaryl, aryl optionally substituted with R.sub.8; n is 0-6; A is COOH, or an acid mimic such as tetraazole, SO.sub.3H, PO.sub.3H, tetronic acid, etc.; R.sub.8 is H, alkyl, cycloalkyl, alkanoyl, halo, OH, perfluoroalkyl, alkoxy, amino, alkylamino, dialkylamino, perfluoroalkoxy; or a **pharmaceutically** acceptable salt thereof; as well as **pharmaceutical** compositions and methods of treatment using these compounds.

L9 ANSWER 6 OF 267 USPATFULL  
AN 2003:40373 USPATFULL  
TI Low fluorescence assay platforms and related methods for drug discovery  
IN Coassin, Peter J., Encinitas, CA, United States  
Harootunian, Alec Tate, Del Mar, CA, United States  
Pham, Andrew A., Del Mar, CA, United States  
Stylli, Harry, San Diego, CA, United States  
Tsien, Roger Y., La Jolla, CA, United States  
PA Aurora Biosciences Corporation, San Diego, CA, United States (U.S. corporation)  
PI US 6517781 B1 20030211  
AI US 2000-476959 20000103 (9)  
RLI Continuation of Ser. No. US 1998-30578, filed on 24 Feb 1998, now patented, Pat. No. US 6171780 Continuation-in-part of Ser. No. US 1997-868049, filed on 3 Jun 1997, now patented, Pat. No. US 5910287 Continuation-in-part of Ser. No. US 1997-867584, filed on 2 Jun 1997 Continuation-in-part of Ser. No. US 1997-868018, filed on 3 Jun 1997 Continuation-in-part of Ser. No. US 1997-867567, filed on 2 Jun 1997  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Warden, Jill; Assistant Examiner: Handy, Dwayne K  
LREP Gray, Cary, Ware & Friedenrich LLP, Haile, Lisa A.  
CLMN Number of Claims: 28  
ECL Exemplary Claim: 1  
DRWN 5 Drawing Figure(s); 4 Drawing Page(s)  
LN.CNT 2383  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB One aspect of the present invention is a multi-well platform for fluorescence measurements, comprising a plurality of wells within a frame, wherein the multi-well platform has low fluorescence background. Another aspect of the present invention is a system for spectroscopic measurements, comprising reagents for an assay and a multi-well platform for fluorescence measurements. A further aspect of the present invention is a method for detecting the presence of an analyte in a sample contained in a multi-well platform by detecting light emitted from the sample. Another aspect of the present invention is a method from identifying a modulator of a biological process or target in a sample contained in a multi-well platform by detecting light emitted from the sample. Another aspect of the present invention is a **composition** identified by this method. A further aspect of the present invention is a method to identify a **therapeutic**. A further aspect of the present invention is a method of testing a **therapeutic** for **therapeutic** activity and toxicology by identifying a

**therapeutic** using a method of the present invention and monitoring the toxicology and efficacy of the **therapeutic** in an in vivo model.

L9 ANSWER 7 OF 267 USPTFULL  
AN 2003:37593 USPTFULL  
TI Optical molecular sensors for cytochrome P450 activity  
IN Makings, Lewis R., Encinitas, CA, UNITED STATES  
Zlokarnik, Gregor, La Jolla, CA, UNITED STATES  
PI US 2003027238 A1 20030206  
AI US 2001-995961 A1 20011127 (9)  
RLI Continuation of Ser. No. US 1999-301525, filed on 28 Apr 1999, PENDING  
PRAI US 1998-112252P 19981214 (60)  
DT Utility  
FS APPLICATION  
LREP KNOBBE MARTENS OLSON & BEAR LLP, 620 NEWPORT CENTER DRIVE, SIXTEENTH  
FLOOR, NEWPORT BEACH, CA, 92660  
CLMN Number of Claims: 45  
ECL Exemplary Claim: 1  
DRWN 7 Drawing Page(s)  
LN.CNT 2790

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides methods of using a compound as an optical probe or sensor of the activity of at least one cytochrome P450 enzyme, and methods of using the compound to screen candidate drugs, and kits for performing these methods. The optical probe of the invention is a compound having the generic structure Y-L-Q, wherein Y is selected from the group consisting of Q as herein defined, saturated C.sub.1-C.sub.20 alkyl, unsaturated C.sub.1-C.sub.20 alkenyl, unsaturated C.sub.1-C.sub.20 alkynyl, substituted saturated C.sub.1-C.sub.20 alkyl, substituted unsaturated C.sub.1-C.sub.20 alkenyl, substituted unsaturated C.sub.1-C.sub.20 alkynyl, C.sub.1-C.sub.20 cycloalkyl, C.sub.1-C.sub.20 cycloalkenyl, substituted saturated C.sub.1-C.sub.20 cycloalkyl, substituted unsaturated C.sub.1-C.sub.20 cycloalkenyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl; L is selected from the group of (--OCR.sup.2H).sub.p--, wherein for each p, all R.sup.2 are separately selected from the group consisting of a hydrogen atom, saturated C.sub.1-C.sub.20 alkyl, unsaturated C.sub.1-C.sub.20 alkenyl, unsaturated C.sub.1-C.sub.20 alkynyl, substituted saturated C.sub.1-C.sub.20 alkyl, substituted unsaturated C.sub.1-C.sub.20 alkenyl, substituted unsaturated C.sub.1-C.sub.20 alkynyl, C.sub.1-C.sub.20 cycloalkyl, C.sub.1-C.sub.20 cycloalkenyl, substituted saturated C.sub.1-C.sub.20 cycloalkyl, substituted unsaturated C.sub.1-C.sub.20 cycloalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, and p is a positive integer no greater than twelve; and Q is a chemical moiety that gives rise to optical properties in its hydroxy or hydroxylate, phenol or phenoxide form that are different from the optical properties that arise from its ether form. Most preferably, p is one, R.sup.2 is hydrogen, and Q is the ether form of a phenoxide fluorophore.

L9 ANSWER 8 OF 267 USPTFULL  
AN 2003:33292 USPTFULL  
TI Optical molecular sensors for cytochrome P450 activity  
IN Makings, Lewis R., Encinitas, CA, United States  
Zlokarnik, Gregor, La Jolla, CA, United States  
PA Vertex Pharmaceuticals (San Diego), LLC, San Diego, CA, United States  
(U.S. corporation)  
PI US 6514687 B1 20030204  
AI US 1999-458927 19991210 (9)  
RLI Continuation-in-part of Ser. No. US 1999-301525, filed on 28 Apr 1999  
PRAI US 1998-112252P 19981214 (60)  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Fredman, Jeffrey; Assistant Examiner: Maupin,

Christine  
LREP Knobbe Martens Olson & Bear LLP  
CLMN Number of Claims: 25  
ECL Exemplary Claim: 1  
DRWN 16 Drawing Figure(s); 16 Drawing Page(s)  
LN.CNT 3297

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides a compound, useful as an optical probe or sensor of the activity of at least one cytochrome P450 enzyme, and methods of using the compound to screen candidate drugs, and candidate drugs identified by these methods. The optical probe of the invention is a compound having the generic structure Y--L--Q, wherein Y is selected from the group consisting of Q as herein defined, saturated C.sub.1-C.sub.20 alkyl, unsaturated C.sub.1-C.sub.20 alkenyl, unsaturated C.sub.1-C.sub.20 alkynyl, substituted saturated C.sub.1-C.sub.20 alkyl, substituted unsaturated C.sub.1-C.sub.20 alkenyl, substituted unsaturated C.sub.1-C.sub.20 alkynyl, C.sub.1-C.sub.20 cycloalkyl, C.sub.1-C.sub.20 cycloalkenyl, substituted saturated C.sub.1-C.sub.20 cycloalkyl, substituted unsaturated C.sub.1-C.sub.20 cycloalkenyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl; L is selected from the group of (--OCR.sup.2H).sub.p--, wherein for each p, all R.sup.2 are separately selected from the group consisting of a hydrogen atom, saturated C.sub.1-C.sub.20 alkyl, unsaturated C.sub.1-C.sub.20 alkenyl, unsaturated C.sub.1-C.sub.20 alkynyl, substituted saturated C.sub.1-C.sub.20 alkyl, substituted unsaturated C.sub.1-C.sub.20 alkenyl, substituted unsaturated C.sub.1-C.sub.20 alkynyl, C.sub.1-C.sub.20 cycloalkyl, C.sub.1-C.sub.20 cycloalkenyl, substituted saturated C.sub.1-C.sub.20 cycloalkyl, substituted unsaturated C.sub.1-C.sub.20 cycloalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, and p is a positive integer no greater than twelve; and Q is a chemical moiety that gives rise to optical properties in its hydroxy or hydroxylate, phenol or phenoxide form that are different from the optical properties that arise from its ether form. Most preferably, p is one, R.sup.2 is hydrogen, and Q is the ether form of a phenoxide fluorophore.

L9 ANSWER 9 OF 267 USPATFULL

AN 2003:30949 USPATFULL

TI Methods of treating inflammatory and immune diseases using inhibitors of IkappaB kinase (IKK)

IN Burke, James R., Holland, PA, UNITED STATES  
Townsend, Robert M., Boothwyn, PA, UNITED STATES  
Qiu, Yuping, Windsor, CT, UNITED STATES  
Zusi, Fred Christopher, Hamden, CT, UNITED STATES  
Nadler, Steven G., Boothwyn, PA, UNITED STATES

PI US 2003022898 A1 20030130

AI US 2002-62847 A1 20020201 (10)

RLI Continuation-in-part of Ser. No. US 2001-965977, filed on 27 Sep 2001, PENDING

PRAI US 2000-223304P 20001003 (60)

US 2001-265853P 20010201 (60)

DT Utility

FS APPLICATION

LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000

CLMN Number of Claims: 50

ECL Exemplary Claim: 1

DRWN 3 Drawing Page(s)

LN.CNT 2898

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention describes methods of preventing and treating inflammatory and immune-related diseases or disorders using inhibitors of I.kappa.B kinase (IKK). Also described are IKK inhibitors effective for the prevention and treatment of inflammatory and immune-related



diseases or disorders, as demonstrated in vivo. Further embodiments of the present invention relate to a specific IKK inhibitors, 4(2'-aminoethyl)amino-1,8-dimethylimidazo(1,2-a) quinoxaline and compounds of formula (I), salts thereof, and **pharmaceutical** compositions.

L9 ANSWER 10 OF 267 USPATFULL  
AN 2003:30941 USPATFULL  
TI Heterocyclic dihydropyrimidine compounds  
IN Atwal, Karnail S., Newtown, PA, UNITED STATES  
Vaccaro, Wayne, Yardley, PA, UNITED STATES  
Lloyd, John, Yardley, PA, UNITED STATES  
Finlay, Heather, Lawrenceville, NJ, UNITED STATES  
Yan, Lin, Princeton, NJ, UNITED STATES  
Bhandaru, Rao S., Belle Mead, NJ, UNITED STATES  
PI US 2003022890 A1 20030130  
AI US 2000-729731 A1 20001205 (9)  
PRAI US 2000-236037P 20000928 (60)  
US 1999-169091P 19991206 (60)  
DT Utility  
FS APPLICATION  
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O  
BOX 4000, PRINCETON, NJ, 08543-4000  
CLMN Number of Claims: 60  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 7238

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel heterocyclic dihydropyrimidine compounds useful as inhibitors of potassium channel function (especially inhibitors of the K.sub.v1 subfamily of voltage gated K.sup.+ channels, especially inhibitors K.sub.v1.5 which has been linked to the ultra-rapidly activating delayed rectifier K.sup.+ current I.sub.Kur), methods of using such compounds in the prevention and treatment of arrhythmia and I.sub.Kur-associated conditions, and **pharmaceutical** compositions containing such compounds.

=> d 119 11-30 bib ab

L19 ANSWER 11 OF 30 USPATFULL  
AN 2001:163218 USPATFULL  
TI N-linked sulfonamides of heterocyclic thioesters  
IN Hamilton, Gregory S., Catonsville, MD, United States  
Li, Jai-He, Cockeysville, MD, United States  
Huang, Wei, Baltimore, MD, United States  
PA GPI Nil Holdings, Inc., Wilmington, DE, United States (U.S. corporation)  
PI US 6294551 B1 20010925  
AI US 2000-516239 20000301 (9)  
RLI Division of Ser. No. US 1997-996342, filed on 22 Dec 1997, now patented, Pat. No. US 6121273 Continuation-in-part of Ser. No. US 1996-775584, filed on 31 Dec 1996, now patented, Pat. No. US 5874449, issued on 23 Feb 1999  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Oswecki, Jane C.  
LREP Nath, Gary M., Juneau, Todd L., Goldberg, Joshua B.  
CLMN Number of Claims: 34  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1658

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to neurotrophic low molecular weight, small molecule N-linked sulfonamides of heterocyclic thioesters having an affinity for FKBP-type immunophilins, and their use as inhibitors of the

enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity.

L19 ANSWER 12 OF 30 USPATFULL

AN 2001:158332 USPATFULL

TI Small molecule inhibitors of rotamase enzyme activity

IN Hamilton, Gregory S., Catonsville, MD, United States

Steiner, Joseph P., Hampstead, MD, United States

PA GPI NIL Holdings, Inc., Wilmington, DE, United States (U.S. corporation)

PI US 6291510 B1 20010918

AI US 1998-73962 19980507 (9)

RLI Continuation-in-part of Ser. No. US 1996-693003, filed on 6 Aug 1996

Continuation of Ser. No. US 1995-479436, filed on 7 Jun 1995, now patented, Pat. No. US 5614547

DT Utility

FS GRANTED

EXNAM Primary Examiner: Gerstl, Robert

LREP Nath, Gary M., Juneau, Todd L., Goldberg, Joshua L.

CLMN Number of Claims: 4

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1284

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to neurotrophic compounds having an affinity for FKBP-type immunophilins, their preparation and use as inhibitors of the enzyme activity associated with immunophilin proteins, and particularly inhibitors of peptidyl-prolyl isomerase or rotamase enzyme activity.

L19 ANSWER 13 OF 30 USPATFULL

AN 2001:131322 USPATFULL

TI N-linked ureas and carbamates of heterocyclic thioesters

IN Hamilton, Gregory S., Catonsville, MD, United States

Li, Jia-He, Cockeysville, MD, United States

Huang, Wei, Chesterfield, MO, United States

PA GPI NIL Holdings, Inc., Wilmington, DE, United States (U.S. corporation)

PI US 6274607 B1 20010814

AI US 1999-393650 19990910 (9)

RLI Division of Ser. No. US 1997-997451, filed on 23 Dec 1997, now patented, Pat. No. US 5958949 Continuation-in-part of Ser. No. US 1996-775585, filed on 31 Dec 1996, now patented, Pat. No. US 5935989

DT Utility

FS GRANTED

EXNAM Primary Examiner: Higel, Floyd D.; Assistant Examiner: Sackey, Ebenezer

LREP Nath, Gary M., Juneau, Todd L., Goldberg, Joshua B.

CLMN Number of Claims: 20

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1942

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to neurotrophic low molecular weight, small molecule N-linked ureas and carbamates of heterocyclic thioesters having an affinity for FKBP-type immunophilins, and their use as inhibitors of the enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity.

L19 ANSWER 14 OF 30 USPATFULL

AN 2001:97914 USPATFULL

TI N-oxides of heterocyclic esters, amides, thioesters, and ketones

IN Hamilton, Gregory S., Catonsville, MD, United States

Steiner, Joseph P., Hampstead, MD, United States

Burak, Eric S., Forest Hill, MD, United States

PA GPI NIL Holdings, Inc., Wilmington, DE, United States (U.S. corporation)

PI US 6251892 B1 20010626

AI US 2000-556482 20000421 (9)

RLI Continuation of Ser. No. US 1998-112319, filed on 9 Jul 1998, now

patented, Pat. No. US 6054542 Continuation of Ser. No. US 1997-807406,  
filed on 28 Feb 1997, now patented, Pat. No. US 5846979, issued on 8 Dec  
1998

DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Seaman, D. Margaret  
LREP Nath, Gary M., Juneau, Todd L., Goldberg, Joshua B.  
CLMN Number of Claims: 33  
ECL Exemplary Claim: 1  
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)  
LN.CNT 1486

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to neurotrophic low molecular weight, small  
molecule N-oxides of heterocyclic esters, amides, thioesters, and  
ketones having an affinity for FKBP-type immunophilins, and their use as  
inhibitors of the enzyme activity associated with immunophilin proteins,  
particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity.

L19 ANSWER 15 OF 30 USPATFULL

AN 2001:82793 USPATFULL  
TI Carbamate and urea compositions and neurotrophic uses  
IN Li, Jia-He, 27 Manor Ct., Cockeysville, MD, United States 21030  
Steiner, Joseph P., 988 Sugar Maple St., Hampstead, MD, United States  
21074  
Hamilton, Gregory S., 6501 Frederick Rd., Catonsville, MD, United States  
21228

PI US 6242468 B1 20010605  
AI US 1998-139672 19980825 (9)  
RLI Continuation-in-part of Ser. No. US 1997-805646, filed on 27 Feb 1997  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Criares, Theodore J.  
CLMN Number of Claims: 44  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1363

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to **pharmaceutical** compositions and  
methods for effecting a neuronal activity using low molecular weight,  
small molecule carbamates and ureas having an affinity for FKBP-type  
immunophilins.

L19 ANSWER 16 OF 30 USPATFULL

AN 2001:56120 USPATFULL  
TI Heterocyclic esters and amides  
IN Li, Jia-He, Cockeysville, MD, United States  
Hamilton, Gregory S., Catonsville, MD, United States  
PA Gpi Nil Holdings, Inc., Wilmington, DE, United States (U.S. corporation)  
PI US 6218544 B1 20010417  
AI US 1999-442628 19991118 (9)  
RLI Division of Ser. No. US 1998-27622, filed on 23 Feb 1998 Division of  
Ser. No. US 1996-719947, filed on 25 Sep 1996, now patented, Pat. No. US  
5801187, issued on 1 Sep 1998

DT Utility  
FS Granted  
EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Rao, Deepak R.  
LREP Nath, Gary M., Juneau, Todd L., Goldberg, Joshua B.  
CLMN Number of Claims: 1  
ECL Exemplary Claim: 1  
DRWN 6 Drawing Figure(s); 2 Drawing Page(s)  
LN.CNT 1052

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to neurotrophic low molecular weight, small  
molecule heterocyclic esters and amides having an affinity for FKBP-type  
immunophilins, and their use as inhibitors of the enzyme activity

associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity.

L19 ANSWER 17 OF 30 USPATFULL  
AN 2001:36819 USPATFULL  
TI Heterocyclic esters and amides  
IN Li, Jia-He, Cockeysville, MD, United States  
Hamilton, Gregory S., Catonsville, MD, United States  
PA GPI NIL Holdings, Inc., Wilmington, DE, United States (U.S. corporation)  
PI US 6200972 B1 20010313  
AI US 1998-27622 19980223 (9)  
RLI Division of Ser. No. US 1996-719947, filed on 25 Sep 1996, now patented,  
Pat. No. US 5801187  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Rao, Deepak R.  
LREP Nath, Gary M., Juneau, Todd L., Goldberg, Joshua B.  
CLMN Number of Claims: 14  
ECL Exemplary Claim: 1  
DRWN 2 Drawing Figure(s); 2 Drawing Page(s)  
LN.CNT 1158  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB This invention relates to neurotrophic low molecular weight, small molecule heterocyclic esters and amides having an affinity for FKBP-type immunophilins, and their use as inhibitors of the enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity.

L19 ANSWER 18 OF 30 USPATFULL  
AN 2001:18489 USPATFULL  
TI N-linked ureas and carbamates of heterocyclic thioesters  
IN Hamilton, Gregory S., Catonsville, MD, United States  
Li, Jia-He, Cockeysville, MD, United States  
Huang, Wei, Baltimore, MD, United States  
PA GPI NIL Holdings, Inc., Wilmington, DE, United States (U.S. corporation)  
PI US 6184243 B1 20010206  
AI US 1998-165372 19981002 (9)  
RLI Division of Ser. No. US 1996-775585, filed on 31 Dec 1996, now patented,  
Pat. No. US 5935989  
DT Utility  
FS Granted  
EXNAM Primary Examiner: McKane, Joseph K.; Assistant Examiner: Sackey, Ebenezer  
LREP Nath & Associates, Nath, Gary M., Juneau, Todd L.  
CLMN Number of Claims: 10  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1091  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB This invention relates to neurotrophic low molecular weight, small molecule N-linked ureas and carbamates of heterocyclic thioesters having an affinity for FKBP-type immunophilins, and their use as inhibitors of the enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity.

L19 ANSWER 19 OF 30 USPATFULL  
AN 2000:174804 USPATFULL  
TI Telomerase catalytic subunit  
IN Cech, Thomas R., Boulder, CO, United States  
Lingner, Joachim, Boulder, CO, United States  
PA University Technology Corporation, Boulder, CO, United States (U.S. corporation)  
Geron Corporation, Menlo Park, CA, United States (U.S. corporation)  
PI US 6166178 20001226  
AI US 1997-974549 19971119 (8)

RLI Continuation-in-part of Ser. No. US 1997-915503, filed on 14 Aug 1997, now abandoned And a continuation-in-part of Ser. No. US 1997-912951, filed on 14 Aug 1997 And a continuation-in-part of Ser. No. US 1997-911312, filed on 14 Aug 1997 which is a continuation-in-part of Ser. No. US 1997-854050, filed on 9 May 1997 which is a continuation-in-part of Ser. No. US 1997-851843, filed on 6 May 1997 which is a continuation-in-part of Ser. No. US 1997-846017, filed on 25 Apr 1997 which is a continuation-in-part of Ser. No. US 1997-844419, filed on 18 Apr 1997 which is a continuation-in-part of Ser. No. US 1996-724643, filed on 1 Oct 1996

PRAI WO 1997-US17618 19971001

WO 1997-US17885 19971001

DT Utility

FS Granted

EXNAM Primary Examiner: Eyler, Yvonne

LREP Townsend and Townsend and Crew LLP

CLMN Number of Claims: 1

ECL Exemplary Claim: 1

DRWN 128 Drawing Figure(s); 103 Drawing Page(s)

LN.CNT 23874

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides compositions and methods related to telomerase reverse transcriptase, the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.

L19 ANSWER 20 OF 30 USPATFULL

AN 2000:125050 USPATFULL

TI N-linked sulfonamides of heterocyclic thioesters

IN Hamilton, Gregory S., Catonsville, MD, United States

Li, Jai-He, Cockeysville, MD, United States

Huang, Wei, Baltimore, MD, United States

PA GPI NIL Holdings, Inc, Wilmington, DE, United States (U.S. corporation)

PI US 6121273 20000919

AI US 1997-996342 19971222 (8)

RLI Continuation-in-part of Ser. No. US 1996-775584, filed on 31 Dec 1996, now patented, Pat. No. US 5874449

DT Utility

FS Granted

EXNAM Primary Examiner: Richter, Johann; Assistant Examiner: Oswecki, Jane C.

LREP Nath & Associates, PLLC, Nath, Gary M., Juneau, Todd L.

CLMN Number of Claims: 24

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1573

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to neurotrophic low molecular weight, small molecule N-linked sulfonamides of heterocyclic thioesters having an affinity for FKBP-type immunophilins, and their use as inhibitors of the enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity.

L19 ANSWER 21 OF 30 USPATFULL

AN 2000:50702 USPATFULL

TI N-oxides of heterocyclic esters, amides, thioesters, and ketones

IN Hamilton, Gregory S., Catonsville, MD, United States

Steiner, Joseph P., Hampstead, MD, United States

Burak, Eric S., Forest Hill, MD, United States

PA GPI NIL Holdings, Inc., Wilmington, DE, United States (U.S. corporation)

PI US 6054452 20000425

AI US 1998-112319 19980709 (9)

RLI Continuation of Ser. No. US 1997-807406, filed on 28 Feb 1997, now

patented, Pat. No. US 8846979  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Seaman, D. Margaret  
LREP Nath & Associates, Nath, Gary M., Juneau, Todd L.  
CLMN Number of Claims: 4  
ECL Exemplary Claim: 1  
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)  
LN.CNT 940

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to neurotrophic low molecular weight, small molecule N-oxides of heterocyclic esters, amides, thioesters, and ketones having an affinity for FKBP-type immunophilins, and their use as inhibitors of the enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity.

L19 ANSWER 22 OF 30 USPATFULL

AN 1999:151234 USPATFULL  
TI Heterocyclic thioesters and ketones  
IN Hamilton, Gregory S., Catonsville, MD, United States  
Li, Jia-He, Cockeysville, MD, United States  
PA Gpi Nil Holdings Inc., Wilmington, DE, United States (U.S. corporation)  
PI US 5990131 19991123  
AI US 1997-904461 19970801 (8)  
RLI Continuation-in-part of Ser. No. US 1996-721765, filed on 25 Sep 1996  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Kight, John; Assistant Examiner: Aulakh, Charanjit S.  
LREP Nath & Associates, Nath, Gary M., Heiman, Lee C.  
CLMN Number of Claims: 58  
ECL Exemplary Claim: 1  
DRWN 13 Drawing Figure(s); 4 Drawing Page(s)  
LN.CNT 1779

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to neurotrophic low molecular weight, small molecule heterocyclic thioesters and ketones having an affinity for FKBP-type immunophilins, and their use as inhibitors of the enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity.

L19 ANSWER 23 OF 30 USPATFULL

AN 1999:117520 USPATFULL  
TI N-linked ureas and carbamates of piperidyl thioesters  
IN Hamilton, Gregory S., Catonsville, MD, United States  
Li, Jia-He, Cockeysville, MD, United States  
Huang, Wei, Chesterfield, MO, United States  
PA GPI NIL Holdings Inc., Wilmington, DE, United States (U.S. corporation)  
PI US 5958949 19990928  
AI US 1997-997451 19971223 (8)  
RLI Continuation-in-part of Ser. No. US 1996-775585, filed on 31 Dec 1996  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Ramsuel, Robert W.; Assistant Examiner: Sackey, Ebenezer  
LREP Nath & Associates, Nath, Gary M., Juneau, Todd L.  
CLMN Number of Claims: 7  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1793

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to neurotrophic low molecular weight, small molecule N-linked ureas and carbamates of heterocyclic thioesters having an affinity for FKBP-type immunophilins, and their use as inhibitors of the enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity.

L19 ANSWER 24 OF 30 USPATFULL  
AN 1999:92704 USPATFULL  
TI N-linked ureas and carbamates of heterocyclic thioesters  
IN Hamilton, Gregory S., Catonsville, MD, United States  
Li, Jia-He, Cockeysville, MD, United States  
Huang, Wei, Baltimore, MD, United States  
PA GPI NIL Holdings Inc., Wilmington, DE, United States (U.S. corporation)  
PI US 5935989 19990810  
AI US 1996-775585 19961231 (8)  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Richter, Johann; Assistant Examiner: Sackey, Ebenezer  
LREP Nath, Gary M., Juneau, Todd L.Nath & Associates  
CLMN Number of Claims: 21  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1206  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to neurotrophic low molecular weight, small molecule N-linked ureas and carbamates of heterocyclic thioesters having an affinity for FKBP-type immunophilins, and their use as inhibitors of the enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity.

L19 ANSWER 25 OF 30 USPATFULL  
AN 1999:24667 USPATFULL  
TI N-linked sulfonamides of heterocyclic thioesters  
IN Hamilton, Gregory S., Catonsville, MD, United States  
Li, Jia-He, Cockeysville, MD, United States  
Huang, Wei, Baltimore, MD, United States  
PA GPI NIL Holdings, Inc., Wilmington, DE, United States (U.S. corporation)  
PI US 5874449 19990223  
AI US 1996-775584 19961231 (8)  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Richter, Johann; Assistant Examiner: Oswecki, Jane C.  
LREP Nath, Gary M., Juneau, Todd L.Nath & Associates  
CLMN Number of Claims: 33  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1340  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to neurotrophic low molecular weight, small molecule N-linked sulfonamides of heterocyclic thioesters having an affinity for FKBP-type immunophilins, and their use as inhibitors of the enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity.

L19 ANSWER 26 OF 30 USPATFULL  
AN 1999:4688 USPATFULL  
TI Small molecule inhibitors of rotamase enzyme activity  
IN Hamilton, Gregory S., Catonsville, MD, United States  
Steiner, Joseph P., Hampstead, MD, United States  
PA GPI NIL Holdings, Inc., Wilmington, DE, United States (U.S. corporation)  
PI US 5859031 19990112  
AI US 1996-650461 19960521 (8)  
RLI Continuation-in-part of Ser. No. US 1995-479436, filed on 7 Jun 1995, now patented, Pat. No. US 5614547  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Gerstl, Robert  
LREP Nath, Gary M., Juneau, Todd L.Nath & Associates  
CLMN Number of Claims: 19  
ECL Exemplary Claim: 1

DRWN 26 Drawing Figure(s); 8 Drawing Page(s)

LN.CNT 1761

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to neurotrophic N-glyoxyl-prolyl ester compounds having an affinity for FKBP-type immunophilins, their preparation and use as inhibitors of the enzyme activity associated with immunophilin proteins, and particularly inhibitors of peptidyl-prolyl isomerase or rotamase enzyme activity.

L19 ANSWER 27 OF 30 USPATFULL

AN 1998:154286 USPATFULL

TI N-oxides of heterocyclic esters, amides, thioesters, and ketones

IN Hamilton, Gregory S., Catonsville, MD, United States

Steiner, Joseph P., Hampstead, MD, United States

Burak, Eric S., Forest Hill, MD, United States

PA GPI NIL Holdings, Inc., Wilmington, DE, United States (U.S. corporation)

PI US 5846979 19981208

AI US 1997-807406 19970228 (8)

DT Utility

FS Granted

EXNAM Primary Examiner: Rotman, Alan L.; Assistant Examiner: Mach, D. Margaret M.

LREP Nath, Gary M., Juneau, Todd L.Nath & Associates

CLMN Number of Claims: 20

ECL Exemplary Claim: 1

DRWN 1 Drawing Figure(s); 1 Drawing Page(s)

LN.CNT 1310

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to neurotrophic low molecular weight, small molecule N-oxides of heterocyclic esters, amides, thioesters, and ketones having an affinity for FKBP-type immunophilins, and their use as inhibitors of the enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity.

L19 ANSWER 28 OF 30 USPATFULL

AN 1998:104757 USPATFULL

TI Heterocyclic esters and amides

IN Li, Jia-He, Cockeysville, MD, United States

Hamilton, Gregory S., Catonsville, MD, United States

PA GPI-NIL Holdings, Inc., Wilmington, DE, United States (U.S. corporation)

PI US 5801187 19980901

AI US 1996-719947 19960925 (8)

DT Utility

FS Granted

EXNAM Primary Examiner: Ivy, C. Warren; Assistant Examiner: Aulakh, Charanjit S.

LREP Nath, Gary M., Juneau, Todd I.Nath & Associates

CLMN Number of Claims: 12

ECL Exemplary Claim: 1

DRWN 6 Drawing Figure(s); 2 Drawing Page(s)

LN.CNT 820

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to neurotrophic low molecular weight, small molecule heterocyclic esters and amides having an affinity for FKBP-type immunophilins, and their use as inhibitors of the enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity.

L19 ANSWER 29 OF 30 USPATFULL

AN 1998:88862 USPATFULL

TI Heterocyclic thioesters

IN Hamilton, Gregory S., Catonsville, MD, United States

Li, Jia-He, Cockeysville, MD, United States

PA GPI Nil Holdings, Inc., Wilmington, DE, United States (U.S. corporation)

PI US 5786378 19980728



AI US 1996-721765 19960925 (8)  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Ivy, C. Warren; Assistant Examiner: Aulakh, Charanjit S.  
LREP Nath, Gary M., Juneau, Todd L.Nath & Associates  
CLMN Number of Claims: 43  
ECL Exemplary Claim: 1  
DRWN 3 Drawing Figure(s); 4 Drawing Page(s)  
LN.CNT 1256  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB This invention relates to neurotrophic low molecular weight, small molecule heterocyclic thioesters and ketones having an affinity for FKBP-type immunophilins, and their use as inhibitors of the enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity.

L19 ANSWER 30 OF 30 USPATFULL  
AN 97:25061 USPATFULL  
TI Small molecule inhibitors of rotamase enzyme  
IN Hamilton, Gregory S., Catonsville, MD, United States  
Steiner, Joseph P., Hampstead, MD, United States  
PA Guilford Pharmaceuticals Inc., Baltimore, MD, United States (U.S. corporation)  
PI US 5614547 19970325  
AI US 1995-479436 19950607 (8)  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Gerstl, Robert  
LREP Nath, Gary M.Nath & Associates  
CLMN Number of Claims: 17  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1116

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB This invention relates to neurotrophic compounds having an affinity for FKBP-type immunophilins, their preparation and use as inhibitors of the enzyme activity associated with immunophilin proteins, and particularly inhibitors of peptidyl-prolyl isomerase or rotamase enzyme activity.

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

STN INTERNATIONAL LOGOFF AT 17:02:52 ON 07 MAR 2003